Show simple item record

dc.contributor.authorBurrows, Caroline
dc.contributor.authorSadowski, Catherine
dc.date.accessioned2021-04-06T20:16:57Z
dc.date.available2021-04-06T20:16:57Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10898/12546
dc.description.abstractNearly 4 million Americans suffer from chronic migraines. These patients have severe headaches that occur for 15 or more days a month, leading to a diminished quality of life. Current recommended therapy is not conducive to all patients, as one study shows 68% of these patients experience at least one medication treatment failure. Within the last few years, the FDA has approved new medications, known as CGRP antagonists, that are proving to be efficacious in the treatment of chronic migraine.
dc.subjectCollege of Health Professions
dc.subjectARC21--Night 3
dc.titleSubcutaneous CGRP Antagonist Injections: A Novel Approach to the Treatment of Chronic Migraines
dc.typePresentation
refterms.dateFOA2021-04-06T20:16:57Z


Files in this item

Thumbnail
Name:
ARC21_COHP_043.pdf
Size:
481.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record